Nomura Asset Management Co. Ltd. Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Nomura Asset Management Co. Ltd. grew its stake in shares of Stryker Co. (NYSE:SYK) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,705 shares of the medical technology company’s stock after acquiring an additional 2,699 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Stryker were worth $26,863,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Private Advisor Group LLC raised its position in Stryker by 1.7% in the third quarter. Private Advisor Group LLC now owns 13,434 shares of the medical technology company’s stock worth $3,670,000 after acquiring an additional 229 shares during the period. NBC Securities Inc. bought a new position in shares of Stryker during the 3rd quarter valued at approximately $541,000. Lincoln National Corp raised its position in shares of Stryker by 1.6% during the 3rd quarter. Lincoln National Corp now owns 7,054 shares of the medical technology company’s stock valued at $1,928,000 after buying an additional 112 shares in the last quarter. Picton Mahoney Asset Management lifted its holdings in shares of Stryker by 20.5% in the 3rd quarter. Picton Mahoney Asset Management now owns 1,030 shares of the medical technology company’s stock valued at $282,000 after acquiring an additional 175 shares during the last quarter. Finally, Childress Capital Advisors LLC purchased a new position in Stryker in the third quarter worth about $290,000. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.90% of the stock is owned by company insiders.

Stryker Trading Up 1.6 %

Shares of NYSE SYK traded up $5.42 during trading on Friday, hitting $335.54. 1,230,572 shares of the company were exchanged, compared to its average volume of 1,514,076. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a fifty day moving average price of $339.85 and a 200-day moving average price of $324.18. The firm has a market capitalization of $127.82 billion, a PE ratio of 38.30, a P/E/G ratio of 2.64 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The business had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.14 earnings per share. As a group, equities research analysts expect that Stryker Co. will post 11.95 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.95%. The ex-dividend date is Friday, June 28th. Stryker’s payout ratio is currently 36.53%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Stifel Nicolaus boosted their target price on Stryker from $350.00 to $375.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Needham & Company LLC raised shares of Stryker from a “hold” rating to a “buy” rating and set a $392.00 price target on the stock in a research note on Wednesday. TD Cowen boosted their price objective on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Roth Mkm raised their target price on shares of Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, UBS Group increased their price objective on Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $370.50.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.